Successful outcome of kidney transplantation from a HBV-DNA positive donor into recipients with cleared HBV-infection using a pre-emptive therapy approach

Journal of Clinical Virology

Volumn 49, Issue 1, 2010, Pages 53-57

  Mohrbach, Janine ^a   Janssen, Martin W W ^a   Heine, Gunnar H ^a   Gärtner, Barbara C ^a   Fliser, Danilo ^a   Sester, Martina ^a   Sester, Urban ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

HBV; Hepatitis B; Pre emptive therapy; T cells; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CADAVER KIDNEY; CASE REPORT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; DELAYED GRAFT FUNCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; INFECTION RISK; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CELL DAMAGE; LIVER FUNCTION; MALE; PATIENT MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 77955659287     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.06.020     Document Type: Article

References (18)

1. Dienstag J.L. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
2. Chung R.T., Feng S., Delmonico F.L. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001, 1:185-191.
3. Levitsky J., Doucette K. Viral hepatitis in solid organ transplant recipients. Am J Transplant 2009, 9:S116-S130. the AST Infectious Diseases Community of Practice.
4. Sester M., Sester U., Gärtner B., Heine G., Girndt M., Mueller-Lantzsch N., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001, 71:1287-1294.
5. Sester U., Gärtner B.C., Wilkens H., Schwaab B., Wössner R., Kindermann I., et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005, 5:1483-1489.
6. Sester U., Presser D., Dirks J., Gärtner B.C., Köhler H., Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008, 8:1486-1497.
7. Deml L., Schirmbeck R., Reimann J., Wolf H., Wagner R. Purification and characterization of hepatitis B virus surface antigen particles produced in Drosophila Schneider-2 cells. J Virol Methods 1999, 79:205-217.
8. Geldmacher A., Skrastina D., Petrovskis I., Borisova G., Berriman J.A., Roseman A.M., et al. An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice. Virology 2004, 323:108-119.
9. von Muller L., Hampl W., Hinz J., Meisel H., Reip A., Engelmann E., et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002, 40:2285-2287.
10. Knoll A., Pietrzyk M., Loss M., Goetz W.A., Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation 2005, 79:1631-1633.
11. Lutwick L.I., Sywassink J.M., Corry R.J., Shorey J.W. The transmission of hepatitis B by renal transplantation. Clin Nephrol 1983, 19:317-319.
12. Jiang H., Wu J., Zhang X., Wu D., Huang H., He Q., et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009, 9:1853-1858.
13. Grady G.F. Transfusions and hepatitis: update in 1978. N Engl J Med 1978, 298:1413-1415.
14. Sester M., Gärtner B.C., Sester U. Monitoring of CMV specific T-cell levels after organ transplantation. J Lab Med 2008, 32:121-130.
15. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77:4911-4927.
16. Webster G.J., Reignat S., Maini M.K., Whalley S.A., Ogg G.S., King A., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000, 32:1117-1124.
17. Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 2010, 107:798-802.
18. Webster G.J., Reignat S., Brown D., Ogg G.S., Jones L., Seneviratne S.L., et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004, 78:5707-5719.